These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21677985)

  • 21. Design, modelling, synthesis and biological evaluation of peptidomimetic phosphinates as inhibitors of matrix metalloproteinases MMP-2 and MMP-8.
    Bianchini G; Aschi M; Cavicchio G; Crucianelli M; Preziuso S; Gallina C; Nastari A; Gavuzzo E; Mazza F
    Bioorg Med Chem; 2005 Aug; 13(15):4740-9. PubMed ID: 15935680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selectivity, binding affinity, and ionization state of matrix metalloproteinase inhibitors.
    Zhong HA; Arbiser J; Bowen JP
    Curr Pharm Des; 2013; 19(26):4701-13. PubMed ID: 23260023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preface - Matrix metalloproteinases.
    Fridman R
    Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt A):1925-1926. PubMed ID: 28739264
    [No Abstract]   [Full Text] [Related]  

  • 24. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors.
    Skiles JW; Gonnella NC; Jeng AY
    Curr Med Chem; 2001 Mar; 8(4):425-74. PubMed ID: 11172697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in assays of matrix metalloproteinases (MMPs) and their inhibitors.
    Cheng XC; Fang H; Xu WF
    J Enzyme Inhib Med Chem; 2008 Apr; 23(2):154-67. PubMed ID: 18343899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The application of x-ray, NMR, and molecular modeling in the design of MMP inhibitors.
    Rush TS; Powers R
    Curr Top Med Chem; 2004; 4(12):1311-27. PubMed ID: 15320728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hydrogen peroxide activated matrix metalloproteinase inhibitors: a prodrug approach.
    Major Jourden JL; Cohen SM
    Angew Chem Int Ed Engl; 2010 Sep; 49(38):6795-7. PubMed ID: 20715043
    [No Abstract]   [Full Text] [Related]  

  • 28. New heteroarylbenzenesulphonamides as matrix metalloproteinase inhibitors.
    Delbecq F; Cordonnier G; Pommery N; Barbry D; Hénichart JP
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1119-21. PubMed ID: 14980648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.
    Scozzafava A; Supuran CT
    Bioorg Med Chem Lett; 2002 Oct; 12(19):2667-72. PubMed ID: 12217351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.
    Jacobson IC; Reddy PG; Wasserman ZR; Hardman KD; Covington MB; Arner EC; Copeland RA; Decicco CP; Magolda RL
    Bioorg Med Chem Lett; 1998 Apr; 8(7):837-42. PubMed ID: 9871551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new role for old ligands: discerning chelators for zinc metalloproteinases.
    Jacobsen FE; Lewis JA; Cohen SM
    J Am Chem Soc; 2006 Mar; 128(10):3156-7. PubMed ID: 16522091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of enzyme activity of and cell-mediated substrate cleavage by membrane type 1 matrix metalloproteinase by newly developed mercaptosulphide inhibitors.
    Hurst DR; Schwartz MA; Jin Y; Ghaffari MA; Kozarekar P; Cao J; Sang QX
    Biochem J; 2005 Dec; 392(Pt 3):527-36. PubMed ID: 16026329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Third generation of matrix metalloprotease inhibitors: Gain in selectivity by targeting the depth of the S1' cavity.
    Devel L; Czarny B; Beau F; Georgiadis D; Stura E; Dive V
    Biochimie; 2010 Nov; 92(11):1501-8. PubMed ID: 20696203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and evaluation of novel oxazoline MMP inhibitors.
    Cook GR; Manivannan E; Underdahl T; Lukacova V; Zhang Y; Balaz S
    Bioorg Med Chem Lett; 2004 Oct; 14(19):4935-9. PubMed ID: 15341955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a receptor-based 3D-QSAR study for the analysis of MMP2, MMP3, and MMP9 inhibitors.
    Tuccinardi T; Nuti E; Ortore G; Rossello A; Avramova SI; Martinelli A
    Bioorg Med Chem; 2008 Aug; 16(16):7749-58. PubMed ID: 18640045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in matrix metalloproteinase inhibitors based on pyrrolidine scaffold.
    Cheng XC; Wang Q; Fang H; Xu WF
    Curr Med Chem; 2008; 15(4):374-85. PubMed ID: 18288992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In silico study of MMP inhibition.
    Rouffet M; Denhez C; Bourguet E; Bohr F; Guillaume D
    Org Biomol Chem; 2009 Sep; 7(18):3817-25. PubMed ID: 19707688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of matrix metalloproteinase inhibitors in cancer therapy.
    Purcell WT; Rudek MA; Hidalgo M
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1189-227. PubMed ID: 12512389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases.
    Levin JI; DiJoseph JF; Killar LM; Sharr MA; Skotnicki JS; Patel DV; Xiao XY; Shi L; Navre M; Campbell DA
    Bioorg Med Chem Lett; 1998 May; 8(10):1163-8. PubMed ID: 9871728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Snapshots of the reaction mechanism of matrix metalloproteinases.
    Bertini I; Calderone V; Fragai M; Luchinat C; Maletta M; Yeo KJ
    Angew Chem Int Ed Engl; 2006 Dec; 45(47):7952-5. PubMed ID: 17096442
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.